CA1261335A — Ethylenediamine monoamide derivatives
Assigned to F Hoffmann La Roche AG · Expires 1989-09-26 · 37y expired
What this patent protects
Abstract It has surprisingly been found that the ethylenedi-amine monoamides of the formula wherein R signifies an aromatic, 5- or 6-membered heterocyclic residue as defined in claim 1, and their pharmaceutically usable acid addition salts have interesting monoamine oxidase inh…
USPTO Abstract
Abstract It has surprisingly been found that the ethylenedi-amine monoamides of the formula wherein R signifies an aromatic, 5- or 6-membered heterocyclic residue as defined in claim 1, and their pharmaceutically usable acid addition salts have interesting monoamine oxidase inhibiting properties with low toxicity and can accordingly be used for the treatment of depressive states and parkinsonism. With the exception of N-(2-aminoethyl)pyridine-2-carboxamide all compounds of formula I are novel; they can be manufactured according to known methods.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.